FDA approves Bristol Myers Squibb's Krazati-cetuximab combo therapy for specific KRAS gene mutation colorectal cancer.
The US FDA has approved Bristol Myers Squibb's combination therapy using the oral drug Krazati and cetuximab for treating colorectal cancer in patients with a specific KRAS gene mutation. The FDA's accelerated approval, based on an early to mid-stage study, showed a 34% partial or complete response rate and increased the time patients lived without disease worsening by 6.9 months. Colorectal cancer, the third most common cancer globally, is the second leading cause of cancer-related deaths worldwide.
June 21, 2024
10 Articles